Overview

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Status:
Recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Accendatech USA Inc.

Collaborators:

Avance Clinical Pty Ltd.
C3 Research Associates

Treatments:

Pembrolizumab